85102-27-8

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine, 7-phenylis used as a drug candidate for its potential antiviral, antibacterial, and anticancer activities. Its unique structure and properties make it a promising candidate for the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
Imidazo[1,2-a]pyridine, 7-phenylis used as a subject of study in medicinal chemistry research to explore its potential applications and mechanisms of action. This can lead to the discovery of new drugs and therapies for various diseases and conditions.

Upstream product

• 60781-83-1 4-phenyl-pyridin-2-ylamine 
• 17157-48-1 bromoacetaldehyde 
• 107-20-0 2-chloroethanal 
• 4532-25-6 7-chloroimidazo-[1,2-a]pyridine 
• 98-80-6 phenylboronic acid 
• 19798-80-2 2-Amino-4-chloropyridine 
• 85102-40-5 2-Morpholinomethyl-1-(3-phenyl-2-propynyl)-imidazole 
• 622402-25-9 tert-butyl (4-phenylpyridin-2-yl)carbamate 
• 405939-28-8 (4-iodopyridin-2-yl)carbamic acid tert-butyl ester 

Downstream Products

• 622402-28-2 7-phenyl-3-pyridin-4-yl-imidazo[1,2-a]pyridine 
• 622402-26-0 3-iodo-7-phenyl-imidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

Pd-Catalyzed Tandem Cyclization via C-H Arylation and Acylation for the Construction of Polycyclic Scaffolds

The first Pd-catalyzed tandem cyclization of imidazo[1,2-a]pyridines with 2-chlorobenzaldehydes through C-H arylation and acylation is presented for the efficient synthesis of novel 6H-benzo[b]imidazo[5,1,2-de]quinolizin-6-ones. The direct acylation react

Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors

The FLT3 kinase represents an attractive target to effectively treat AML. Unfortunately, no FLT3 targeted therapeutic is currently approved. In line with our continued interests in treating kinase related disease for anti-FLT3 mutant activity, we utilized pioneering synthetic methodology in combination with computer aided drug discovery and identified low molecular weight, highly ligand efficient, FLT3 kinase inhibitors. Compounds were analyzed for biochemical inhibition, their ability to selectively inhibit cell proliferation, for FLT3 mutant activity, and preliminary aqueous solubility. Validated hits were discovered that can serve as starting platforms for lead candidates.

Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.